Compensated Awareness Post View
Disclaimer
Biostage, Inc. (BSTG) – Developing Personalized Approach to Organ Regeneration
Biostage, Inc. (NASDAQ: BSTG) is pioneering radically new technologies for the development of bioengineered organ implants targeting cancer and other life-threatening diseases of the esophagus, bronchus, and trachea. Traditional treatment options for such diseases are limited, with significant risk of complications and negative effect on quality of life. The company’s Cellframe™ technology uses the patient’s own stem cells to seed onto a proprietary biocompatible scaffold designed to guide the regeneration of a biological structure matching the dimensions of the organ being regenerated. The resulting organ-specific “Cellspan” implants represent a unique personalized approach to organ regeneration.
Biostage has worked long to evolve their revolutionary Cellframe™ technology, which, in the company’s words, “combines the best attributes of a synthetic scaffold with tissue engineering and cell biology,” creating a platform representing “a complete re-engineering” of their earlier organ scaffold and cell technology. In May 2016, Biostage announced successful results from large-animal studies of their Cellspan Esophageal Implant, conducted in conjunction with Mayo Clinic, and the company is in the process of getting these results published in a peer-reviewed scientific journal, an important step toward full recognition. The company plans to file an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA), and it expects to conduct human clinical trials in 2017. The goal of these clinical trials is to demonstrate the technology’s superior mortality rates, with reduced complications and improved quality of life for patients.
The company’s stated values are based upon its management team’s belief that its proprietary Cellframe technology has the “opportunity to dramatically advance the field of regenerative medicine by improving the treatment options for patients with life-threatening conditions,” with an overall target of “breakthrough solutions for unmet medical needs.”
The Chief Executive Officer of Biostage, Jim McGorry, has over 30 years of leadership experience with a number of companies in the medical and biotech industries, in addition to carrying an MBA with a concentration in healthcare from Duke University, and a BS in Engineering from West Point. He also served as an officer in the United States Army for six years, including commanding a special operations Green Beret SCUBA detachment.
For more on Biostage, visit www.biostage.com
